Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection

A postmarketing Cohort study of Melanoma patients treated with IMLYGIC (Talimogene Laherparepvec) in clinical Practice to Characterize the risk of herpetic infection with detection of Talimogene Laherparepvec DNA among patients, close contacts, and health care providers; and long term safety in treated patients for up to 5 years after the first IMLYGIC dose.

Additional locations may be listed on ClinicalTrials.gov for NCT02910557.

See trial information on ClinicalTrials.gov for a list of participating sites.

Trial PhaseNo phase specified

Trial TypeNot provided by clinicaltrials.gov

Lead OrganizationAmgen, Inc.

• Primary ID20130193
• Secondary IDsNCI-2019-06388
• ClinicalTrials.gov IDNCT02910557